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 2 
ABSTRACT 21 
Candidaemia is widely reported as the fourth most common form of bloodstream 22 
infection worldwide. Reports of breakthrough cases of candidaemia are 23 
increasing, especially in the context of a move away from azole antifungals as 24 
prophylactic or first line treatment towards the use of echinocandin agents. The 25 
global evaluation of echinocandin antifungal susceptibility since 2003 has 26 
included switches in testing methodologies and the move to a sentinel 27 
echinocandin approach for classification reporting. This study compiles 28 
previously unpublished data from echinocandin susceptibility testing of UK 29 
clinical isolates of C. glabrata received at the Public Health England Mycology 30 
Reference Laboratory from 2003 to 2016, and re-evaluates the prevalence of 31 
resistance in light of currently accepted testing protocols. From 2015 onwards, 32 
FKS gene mutation detection using a novel Pyrosequencing® assay was assessed 33 
as a predictor of echinocandin resistance alongside conventional susceptibility 34 
testing.  35 
Overall, our data show that echinocandin resistance in UK isolates of C. glabrata 36 
is a rare phenomenon and prevalence has not appreciably increased in the last 37 
14 years.  The pyrosequencing assay was able to successfully detect hot spot 38 
mutations in FKS1 and FKS2, although not all isolates that exhibited phenotypic 39 
resistance demonstrated detectable hot spot mutations. We propose that a rapid 40 
genomic based detection method for FKS mutations, as part of a multifactorial 41 
approach to susceptibility testing, could help provide accurate and timely 42 
management decisions especially in regions where echinocandin resistance has 43 
been reported to be emerging in this important pathogen. 44 
(Word Count: 239)  45 
 3 
INTRODUCTION 46 
 47 
Candidaemia, which is widely reported as the fourth most common form of 48 
bloodstream infection worldwide, presents a considerable challenge to modern 49 
medicine. An increase in resistance to established antifungal agents and changing 50 
patient demographics are helping to widen the spectrum of species able to cause 51 
infection 1-3. The appropriate use of antifungal drugs is essential for timely and 52 
successful clinical outcomes, helping to reduce the burden of emergent 53 
resistance and financial strain upon healthcare providers 4-6. In most countries, 54 
Candida glabrata continues to be the second most commonly isolated cause of 55 
candidaemia after Candida albicans, with some healthcare providers indicating 56 
an increase in prevalence 7. A member of the Nakaseomyces clade alongside C. 57 
nivariensis and C. bracarensis, C. glabrata presents added complications for 58 
clinicians as a significant proportion of isolates exhibit elevated minimum 59 
inhibitory concentrations (MICs) to the triazole antifungal agents in general in 60 
vitro, and in particular to fluconazole 8-10.  61 
 62 
The echinocandin antifungal class primarily consists of caspofungin (CSP), 63 
anidulafungin (ANF) and micafungin (MCF). These agents are acylated cyclic 64 
hexapeptides, which demonstrate some fungicidal activity by non-competitively 65 
inhibiting β-1, 3-glucan synthase and represent a niche class of antifungal agents 66 
for treatment of candidaemia. However, breakthrough cases of infection are 67 
increasingly being reported, especially in the context of an increase in 68 
echinocandin use for prophylactic coverage or as a first line treatment 69 
alternative to fluconazole 11-16. Indeed, several studies have reported the 70 
 4 
potential for rapid acquisition of echinocandin resistance 11-12, with resistance 71 
rates as high as 13.5% observed within one US healthcare centre13. 72 
 73 
Well-established methodologies for in vitro susceptibility testing in the clinical 74 
laboratory are used to determine the MIC of an antifungal agent 17-18. However, 75 
methods of testing are both labour intensive and time consuming with results 76 
typically available to clinicians only 48-72 hours post isolation 17. This can result 77 
in poor or ineffective empirical treatment decisions that require alteration 78 
following interpretation of laboratory results 18. Further compounding such 79 
method restrictions is the inter-laboratory variability demonstrated when CSP 80 
alone is used for determination of MIC value. Consequently it has been reported 81 
that the use of CSP could lead to an over reporting of resistance 19. Efforts to 82 
streamline established methods have demonstrated some success; especially 83 
with C. glabrata although the time from isolation to result is still limited by the 84 
requirement for further or repeat growth of the organism before an 85 
interpretation of results can be made, for example between 24-48 hours for E-86 
test 17-20. 87 
 88 
A major mechanism for echinocandin resistance in Candida sp. has been 89 
attributed to so-called hot spot mutations within the FKS gene. First described in 90 
Candida albicans, this gene has been shown to encode a large integral membrane 91 
protein suspected to be β-1, 3-glucan synthase 21. Distinct mutations within this 92 
gene region have been described in isolates demonstrating resistance to 93 
echinocandin antifungal agents 22-24, and it has been suggested that the presence 94 
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of an FKS mutation rather than an MIC value is an independent risk factor in the 95 
prediction of the outcome of echinocandin usage 24-25. 96 
 97 
In the last decade, genomic and proteomic technologies such as 98 
Pyrosequencing® and matrix-assisted laser desorption ionisation time of flight 99 
mass spectrometry (MALDI-TOF MS) have revolutionised the speed and accuracy 100 
of identification of clinical isolates of fungi in the diagnostic laboratory 26-28. 101 
While work continues to evaluate the use of proteomics for susceptibility testing 102 
30-31, there remains a clinical need for accurate and rapid detection of resistance. 103 
Although genomic approaches such as Pyrosequencing for isolate identification 104 
have somewhat been eclipsed by MALDI-TOF MS, the repurposing of this 105 
technology due to its unique chemistry, speed and ease of use for reliable 106 
sequencing of short regions of DNA could be useful for the detection of resistance 107 
markers. Other alternative rapid PCR based methodologies and asymmetric PCR 108 
coupled with allele-specific molecular beacons have also previously been 109 
employed to determine the presence of FKS1 and/or FKS2 mutants 31-32.  110 
 111 
The UK National Mycology Reference Laboratory (MRL) at Public Health England 112 
(PHE) provides clinical and diagnostic services for the entire United Kingdom 113 
and processes in excess of 5000 isolates of pathogenic yeast for susceptibility 114 
testing annually. Isolates are referred from local, regional and national centres 115 
throughout the UK and Ireland. The main aim of this study was to retrospectively 116 
analyse MIC data generated at the MRL from the start of echinocandin testing in 117 
2003 up to the end of 2016. This data has been reviewed with consideration to 118 
the patterns of changing opinion regarding methodological restrictions, shifting 119 
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clinical breakpoints and inter-laboratory variations to provide a clearer picture 120 
of the prevalence of echinocandin resistance in the UK. From 2015 onwards, a 121 
Pyrosequencing platform was employed in parallel as a real-time detector of FKS 122 
mutations, and therefore echinocandin resistance. 123 
 124 
  125 
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MATERIALS & METHODS 126 
 127 
Clinical Isolates for Minimum Inhibitory Concentration (MIC) testing 128 
All isolates were subcultured onto Sabouraud dextrose agar with 129 
chloramphenicol (SABC; PO0161A; Oxoid Ltd, Basingstoke, Hampshire, UK) and 130 
incubated at 30°C for 48 hours. 131 
Minimum inhibitory concentrations (MIC) were collated for all clinical isolates of 132 
C. glabrata referred to the PHE MRL between 2003 and July 2016. Isolates were 133 
identified according to standard protocols employed at our laboratory as follows. 134 
Isolates received between 2002 and December 2007 were identified by a combination 135 
of AUXACOLOR2/API 20C in conjunction with 26S rRNA gene sequencing 
33
; from 136 
January 2008 through May 2012 all isolates were identified by Pyrosequencing of a 137 
portion of the internal transcribed spacer region 2 
28
; from May 2012 through July 138 
2018 all isolates were identified by MALDI-TOF 
27
.   139 
 140 
Susceptibility testing was either performed using E-test (MCF from 2002; CSP 141 
from 2012; ANF as confirmation of resistance) as provided by BioMérieux 142 
(Product code 532418) and using RPMI agar (BioMérieux AEB122180) or by 143 
CLSI microbroth dilution (CSP between 2002 and 2012; ANF from 2002) as 144 
previously described 17-18. Throughout the time period, various breakpoints were 145 
used in accordance with published data at the time 34-38. At the PHE MRL, 146 
susceptibility cut off values of 0.25μg/mL for CSP and ANF, and 0.125μg/mL for 147 
MCF were used to indicate the likelihood of resistance. This is primarily because 148 
an interpretation of “intermediate” is of little value to the clinician, and would 149 
ultimately result in that particular agent not being used but also as this value has 150 
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previously demonstrated high sensitivity and specificity for the selection of FKS 151 
mutants 39.  152 
Archived isolates of C. glabrata stored in the National Collection of Pathogenic 153 
Fungi (NCPF) were used as control strains and were selected based upon 154 
previous antifungal resistance testing, where phenotypic resistance to the 155 
echinocandin class of antifungal agents had been demonstrated; generally this 156 
was achieved by CLSI microbroth dilution testing against CSP 36. All archived 157 
isolates were subjected to confirmatory echinocandin resistance testing by 158 
established methods prior to sequencing analysis for FKS mutations 37. 159 
 160 
Pyrosequencing and rapid detection of FKS mutants 161 
During the period from July 2015 to July 2018, all clinical isolates of C. glabrata 162 
submitted to the PHE MRL for susceptibility testing which exhibited phenotypic 163 
resistance to an echinocandin agent were subjected to Pyrosequencing for the 164 
detection of FKS mutations. 165 
Biotinylated forward primers were created based on the position of FKS 166 
mutations that confer echinocandin resistance to strains in vitro as previously 167 
described for Saccharomyces cerevisiae and Candida albicans 40-41 and resembled 168 
CgFKS1, GenBank accession no. KF211456.1 [12] and CgFKS2, GenBank accession 169 
no. HM366442.142. The reverse primer (20μM CgFKS1/2 reverse) was used as 170 
the Pyrosequencing analysis primer. PyroMark™ID (Biotage AB, Uppsala, 171 
Sweden) was used to perform the Pyrosequencing protocol as previously 172 
described 28. To enable the real-time analysis of sequences generated by the 173 
IdentiFire® Pyrosequencing analysis software (Biotage AB, Uppsala, Sweden), 174 
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the creation of a FASTA format file was necessary for each possible mutation and 175 
wild type (WT) sequence within FKS1 and FKS2.  176 
 177 
RESULTS & DISCUSSION 178 
 179 
Re-evaluation of MIC data in the context of changing laboratory protocols 180 
 181 
In total from 2003 to 2018, 7,225 clinical isolates of C. glabrata were tested for 182 
echinocandin susceptibility at the PHE MRL. Between 2003 and 2016 there was a 183 
considerable shift in MIC values reported for C. glabrata when tested against CSP 184 
(Table 1). This followed the acknowledgement that species-specific breakpoints 185 
were required 37 and as reported by Espinel-Ingroff et al. (2013), that CLSI 186 
testing of CSP was considered too variable between laboratories to reliably 187 
indicate resistance.  In the first decade of echinocandin testing from 2003 to 188 
2013, MIC values by CLSI methodology indicated resistance prevalence ranging 189 
from 0.3- 7.9% with a mean of 3.4% using the CLSI breakpoints in operation at 190 
the time of antifungal susceptibility testing. In fact, when current breakpoints are 191 
retrospectively applied to this historical data, the vast majority of isolates 192 
exhibited MICs which fall in the non-susceptible range, in complete agreement 193 
with Espinell-Ingroff et al. that caspofungin susceptibility testing by broth 194 
microdilution artificially inflates resistance rates19. With the introduction of the 195 
use of ANF as the sentinel echinocandin and E-test for specific CSP testing, this 196 
prevalence range was reduced to 0.9-2.7% with a mean of 1.5%.  Data from 2012 197 
is difficult to interpret due to the fact that both testing methods were in use and 198 
the breakpoints were under review so the point prevalence rate of 5.9% is 199 
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artificially raised and does not indicate emergent or outbreak resistance. In fact, 200 
if the data is re-assessed using the 2017 higher breakpoint cut off then 201 
prevalence drops to 1.1% (2/185) 37. 202 
The total prevalence of 2.8% resistance to micafungin is artificially elevated in 203 
this data set as it was principally employed to confirm resistance detected with 204 
the other echinocandins prior to 2015. 205 
 206 
This study provides evidence that the prevalence of echinocandin resistance in 207 
clinical isolates of C. glabrata in the UK remains very low at 0.55% between 2015 208 
and 2018 when testing is optimised. This correlates with studies conducted in 209 
other European countries and China 10, 43-45, and appears consistent with the re-210 
evaluated in vitro data generated prior to this timeframe. 211 
 212 
Analysis of FKS mutation detection as a predictor of resistance 213 
 214 
Of the 2713 C. glabrata isolates subjected to antifungal susceptibility testing at 215 
the PHE MRL between July 2015 and July 2018, fifteen (0.55%) exhibited some 216 
degree of phenotypic resistance to one or more echinocandin agent. The details 217 
for each isolate can be found in Table 2. Eleven isolates demonstrated MICs in 218 
the resistant range for at least two of the echinocandin antifungal agents 219 
(isolates 61, 71-76, 78-81), two further isolates had resistant MICs with 220 
caspofungin, intermediate MICs with anidulafungin but susceptible MICs with 221 
micafungin (isolates 67 and 77), and the final 2 isolates (68 and 70) had 222 
intermediate MICs with caspofungin alone, which was the only echinocandin 223 
tested. Of particular note, 6/15 (40%) isolates originated from blood, and 10/15 224 
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(66%) isolates were referred from different centres within the geographical 225 
region of London. None of the isolates in this study represented repeat isolations 226 
from the same patient, although 3/15 (20%) did originate at the same London 227 
centre. However, they were isolated 2 months and 6 months apart.  228 
 229 
FKS mutations detected by Pyrosequencing are displayed in Table 3. In total, 230 
6/15 (40%) isolates demonstrated a mutation in FKS1, with 6/6 (100%) of the 231 
detected mutations representing an amino acid substitution of serine for proline 232 
at position 629 (S629P). For FKS2, 4/15 (26.7%) isolates showed an indisputable 233 
mutation, with again 4/4 (100%) representing a serine to proline substitution 234 
but at position 663 (S663P). The presence of a single mutation in either FKS1 or 235 
FKS2 was sufficient to confer resistance to all echinocandin agents. Isolates 71 236 
and 72 may have mutations in both regions but despite repeat testing, the 237 
sequence homology score for FKS2 was never greater than 90% as shown in 238 
Table 3. Isolates 61 and 80 failed to show any evidence of amplification for the 239 
FKS2 region on repeated attempts and are listed as inconclusive for mutations in 240 
this region. In the case of isolate 80, FKS1 demonstrated a wild type sequence. 241 
Of those isolates demonstrating some degree of phenotypic resistance, 4/15 242 
(26.7%) did not apparently possess a mutation in either FKS1 or FKS2 (isolates 243 
67, 68, 70 and 77). However, all 4 isolates demonstrated MIC values that flanked 244 
the cut-off value (0.25 – 0.5μg/mL) and as such could be considered 245 
phenotypically borderline resistant/non-susceptible. Generally, when the MIC 246 
was at least 2 doubling dilutions greater than the susceptibility cut-off value, 247 
there was an associated FKS mutation in either FKS1 or FKS2. The exception was 248 
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isolate 71 where MICs to ANF and CSP were within 2 doubling dilutions from the 249 
cut off value but an FKS1 mutation was detected.  250 
 251 
Developing technological approaches using MALDI-TOF MS have demonstrated 252 
their potential for the detection of resistance mechanisms. However, the financial 253 
constraints of acquiring the platforms, coupled with time limitations, whereby a 254 
minimum incubation time of 6 hours post isolation is required prior to a result 255 
being reported 29-30, suggests there is scope for alternative methodologies. The 256 
Pyrosequencing assay described here has a minimum detection time of 4 hours 257 
post isolation, and many clinical laboratories may already have access to the 258 
platform without further expenditure. Whilst this study used log phase growth, 259 
freshly subcultured from referred isolates, it would be possible to perform the 260 
Pyrosequencing assay directly on isolates at the point of receipt or isolation as 261 
previously demonstrated 27-28. Interestingly, some studies have evaluated the use 262 
of Pyrosequencing directly from blood cultures and found >90% success rates in 263 
identifying bacterial species 46-47. This suggests there exists the possibility of 264 
running the FKS assay without the need for secondary subculture or incubation 265 
of tests and thereby reducing the time to implement corrective therapeutic 266 
management. 267 
This highlights the potential for the use of Pyrosequencing as a baseline 268 
screening procedure or empiric antifungal triage service for all isolates referred 269 
to the reference laboratory, or in centres were emergent resistance has been 270 
demonstrated. This could significantly reduce time and financial impacts, with a 271 
possible reduction in the selection/alteration of antifungal regimes within 24 272 
hours, a direct contrast to many susceptibility test protocols 17-18.  273 
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 274 
In agreement with the published literature, the current study has underscored 275 
the utility of FKS mutation detection in predicting frank echinocandin resistance, 276 
in that all isolates exhibiting resistant MICs with at least two echinocandin 277 
antifungal agents had demonstrable FKS hot spot mutations. However, three 278 
isolates that did not have FKS mutations phenotypically, demonstrated MICs that 279 
would be considered intermediate to CSP and as such they would not be 280 
recommended as therapeutic options. A similar situation was reported recently 281 
from a US study 48 that found phenotypic non-susceptibility to micafungin in the 282 
absence of detectable FKS mutations. This further supports the continued role of 283 
susceptibility testing of individual isolates in the determination of appropriate 284 
antifungal agents for therapeutic selection as advised in the current guidelines of 285 
the ESCMID fungal infections study group, as well as the continued use of 286 
anidulafungin or micafungin as indicators of true echinocandin resistance 38-39. It 287 
was difficult to ascertain a high confidence sequence read (>99% 288 
coverage/identity) for FKS2 with two of the clinical isolates (isolates 71 and 72). 289 
This could be due to multiple factors, including short primer length, or quality of 290 
the initial PCR amplification products. The two isolates are unrelated in terms of 291 
isolation and geographical region, and the suggested mutation (S663F), if 292 
present, has previously been associated with echinocandin resistance 22. 293 
However, since both isolates also harboured S629P mutations in FKS1, we 294 
cannot conclude definitively on the presence of the purported FKS2 mutation on 295 
the basis of observed phenotypic echinocandin resistance. It has previously been 296 
demonstrated that the efficiency of Pyrosequencing is optimised over a region of 297 
30-35 bases 28. In order to capture all of the possible FKS hot spot mutation 298 
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regions, this had to be extended to up to 45 bases and it is possible that the 299 
internal chemistry of the assay becomes too unreliable at this length, resulting in 300 
low score matches as observed with some FKS2 sequences. Sequence homology 301 
scores less than 100% must be treated with caution when a single base point 302 
alteration can result in the mutation of the gene, especially if it occurs within a 303 
hot spot region. This study does not account for mutations that may be present 304 
in FKS3 recently shown to act as a negative regulator of echinocandin 305 
susceptibility in C. albicans 49. 306 
 307 
It is important to note that as a reference laboratory, PHE MRL data is often 308 
skewed due to the fact that we receive predominantly those isolates that regional 309 
or local laboratories find difficult to interpret or require confirmatory testing for.  310 
Even so, the MIC data collected from testing using E-test for CSP and MCF and 311 
CLSI for ANF prior to the FKS mutation detection trial, demonstrates a low 312 
echinocandin resistance rate of around 0.9-1.5%, similar to that reported 313 
recently from a US study which found reduced micafungin susceptibility and/or 314 
demonstrable FKS mutations in 33 of 3876 (0.85%) isolates of Candida spp  and 315 
12/832 (1.44%) of isolates of C. glabrata 48. However, with the increase in 316 
commercially available microbroth dilution systems which include all three 317 
currently available echinocandin agents (e.g. Sensititre Yeast One™, Thermo 318 
Fisher), and as more laboratories move towards in-house testing it is important 319 
that laboratories using these platforms are aware of the difficulties in 320 
interpreting CSP MIC values and potential consequences. When testing CSP, 321 
results may be reported as intermediate or resistant however CLSI recommend 322 
that confirmatory testing is performed either using ANF or MCF, DNA analysis to 323 
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confirm FKS hot spot mutation or by sending to a reference laboratory 38. 324 
Regardless of CSP MIC result, CLSI recommend that if either of these first two 325 
criteria is fulfilled then pan-echinocandin resistance is confirmed and should be 326 
reported. 327 
 328 
Interestingly, 3/5 (60%) of the revived NCPF isolates did not exhibit any 329 
phenotypic resistance to the echinocandin agents, and indeed did not possess 330 
demonstrable mutations in FKS1 or FKS2 (data not shown). This finding may 331 
indicate the potential loss of acquired resistance mechanisms post storage or 332 
revival, mis-cataloguing of accession cultures, or more likely is due to re-333 
interpretation of MIC results in light of changing susceptibility breakpoints. This 334 
serves to highlight the importance of validating culture collection strains or 335 
strains stored for long periods of time prior to use in research 50.  336 
 337 
In conclusion, the rapid detection of existing, or emergent resistance before or 338 
during treatment with antifungal agents is going to be a vital tool in allowing 339 
successful targeted antimicrobial therapy. This will form the underlying basis of 340 
many antifungal stewardship program’s as we enter an era of broad spectrum 341 
antimicrobial resistance. The detection of FKS mutations can provide an 342 
appropriate indication of the correct antifungal regime selection and the power 343 
of this study is that it demonstrates how an existing diagnostic laboratory 344 
technology can be adapted and primed for the eventual emergence of resistance.  345 
With very little funding or motivation for the development of novel antifungal 346 
agents, the echinocandin class of antifungals remains an important example of 347 
unique mode of action agents within a narrow field of therapeutic options for the 348 
 16 
treatment of candidaemia. It is imperative that advances and technologies such 349 
as demonstrated in this study, are readily deployable should a situation arise 350 
where echinocandin resistance increases. This highlights the need for the 351 
development of resistance detection approaches and the importance of accurate 352 
susceptibility testing and interpretation at local and regional levels. 353 
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